Testing drug sensitivity in solid tumors using needle biopsies.
Official title: MetaboCore: Needle biopsy assay of drug sensitivity for solid tumors.
Funded at University of Washington · NIH-10858769 · Data updated 2026-11-12
This study is testing a new way to help doctors find the best cancer treatments for patients by looking at how their tumors respond to different drugs using fresh samples, so they can get quicker and more personalized care.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 19, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $401,113 |
| NIH project number | 1U01CA281433-01A1 |
| Project ID | NIH-10858769 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with solid tumors who are undergoing needle biopsy procedures.
✕Less likely to help
Patients with blood cancers or those who are not undergoing biopsy procedures may not benefit from this research.
What this research studies
This research focuses on improving personalized cancer treatment by developing a new assay that evaluates how sensitive a patient's tumor is to various drugs. Using fresh tumor tissues obtained through needle biopsies, the MetaboCore assay measures metabolic changes in cancer cells shortly after drug exposure. This approach aims to provide oncologists with quick and reliable results, allowing for more tailored treatment options for patients. The research will also establish standardized procedures to ensure consistent and reproducible outcomes.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective cancer treatments tailored to individual patients' tumors.
How similar studies have gone: Previous research has shown promise in using metabolic assays for drug sensitivity testing, but this specific approach is novel and aims to overcome existing limitations.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Yeung, Raymond — University of Washington
- Study coordinator: Yeung, Raymond
Related research
Other NIH-funded projects on the same topics.
-
Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors
A program uses mouse tumor models to identify promising drug candidates for children with sarcoma and other solid tumors.
-
Engineered CAR T immune cells targeting GPC3 for children's solid tumors
Engineered CAR T immune cells that produce IL-15 and IL-21 to better find and fight GPC3-positive solid tumors in children.
-
Boosting CAR T cell power in solid tumors by turning on transcription factors
A new research project tests whether turning on specific human transcription factors can make CAR T cells work better against solid tumors.
-
Engineering CD19 mimotopes to boost and broaden CD19-CAR T cell therapy
A patient-focused look at improving existing CD19-CAR T cell therapy so more people with blood cancers might benefit.
-
Radio-triggered CAR-T cells to better control solid tumors
A new approach uses radiation to turn on and guide CAR-T cells to fight solid tumors more effectively, potentially improving local and distant tumor control for patients with cancer.
-
Understanding how cell behavior changes drive breast cancer in 3D cultures
Researchers are studying how breast cells transition toward cancer using advanced 3D cultures and patient-derived samples to uncover important cell-state changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.